Eric J. Hyllengren
Known title: SVP, CFOCIK: 0001966926
Associated companies
Transaction History
| ATRA | ▼ Sell | Open Market | 1,211 | $8K | 3/3/2025 | View on chart |
| ATRA | ▲ Buy | Grant | 34,050 | $0 | 1/27/2025 | View on chart |
| ATRA | ▼ Sell | Open Market | 1,364 | $15K | 11/18/2024 | View on chart |
| ATRA | ▼ Sell | Open Market | 1,041 | $7K | 8/16/2024 | View on chart |
| ATRA | ▼ Sell | Open Market | 29 | $192 | 8/16/2024 | View on chart |
| ATRA | ▼ Sell | Open Market | 28,648 | $18K | 5/16/2024 | View on chart |
| ATRA | ▼ Sell | Open Market | 5,217 | $4K | 3/4/2024 | View on chart |
| ATRA | ▼ Sell | Open Market | 1,462 | $1K | 3/4/2024 | View on chart |
| ATRA | ▲ Buy | Grant | 475,000 | $0 | 1/8/2024 | View on chart |
| ATRA | ▼ Sell | Open Market | 11,958 | $5K | 11/16/2023 | View on chart |
| ATRA | ▼ Sell | Open Market | 6,408 | $11K | 8/16/2023 | View on chart |
| ATRA | ▼ Sell | Open Market | 1,778 | $3K | 8/16/2023 | View on chart |
| ATRA | ▼ Sell | Open Market | 6,199 | $13K | 5/16/2023 | View on chart |
| ATRA | ▼ Sell | Open Market | 1,719 | $4K | 5/16/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Atara Biotherapeutics Resubmits Tabelecleucel BLA to FDA
Atara Biotherapeutics and its partner Pierre Fabre have filed a new biologics license application for the Tabelecleucel therapy with the U.S. FDA. The resubmission follows the earlier filing and reflects the companies' effort to move the product toward approval. The stock is currently near a long‑standing support level, which may be watched as the regulatory process continues.
Atara Biotherapeutics Resubmits Tabelecleucel BLA to FDA. Atara Biotherapeutics and its partner Pierre Fabre have filed a new biologics license application for the Tabelecleucel therapy with the U.S. FDA. The resubmission follows the earlier filing and reflects the companies' effort to move the product toward approval. The stock is currently near a long‑standing support level, which may be watched as the regulatory process continues.